NAVIDEA BIOPHARMACEUTICALS, INC.
NAVBHealthcare · In Vitro & In Vivo Diagnostic Substances · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $14,645 | $45,615 | $119,000 | $38,000 | $338,000 | $1.8M |
| Operating income | −$14.1M | −$12.1M | −$10.7M | −$11.0M | −$10.8M | −$13.9M |
| Net income | −$15.2M | −$11.7M | −$10.7M | −$10.9M | −$16.1M | $74.9M |
| Total assets | $4.4M | $6.6M | $7.8M | $4.2M | $7.0M | $20.8M |
| Total liabilities | $12.5M | $6.0M | $5.7M | $5.0M | $4.6M | $8.7M |
| Equity | −$8.4M | −$106,556 | $1.3M | −$1.6M | $1.7M | $11.4M |
| EPS (diluted) | $-0.56 | $-0.40 | — | — | $-0.09 | $0.45 |
| Shares out. | 30.3M | 28.6M | 20.4M | 200.7M | 162.8M | 161.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −95943.3%
- Net margin
- −103633.7%
- Return on equity
- 179.9%
- Return on assets
- −347.2%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 286.3%
- Debt / equity
- —
- Book value / share
- $-0.28
- Revenue growth (YoY)
- −67.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -321.76distress
- Accruals / assets
- −141.6%clean
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 16, 2017
- NT 10-Qmissed a reporting deadline ↗Aug 10, 2016
- NT 10-Qmissed a reporting deadline ↗May 10, 2016
- NT 10-Kmissed a reporting deadline ↗Mar 16, 2016
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Sep 30, 2025 | 466 | 1.0 | +18.3% |
| Sep 15, 2025 | 394 | 1.0 | 0.0% |
| Aug 29, 2025 | 394 | 1.0 | 0.0% |
| Aug 15, 2025 | 394 | 1.0 | 0.0% |
| Jul 31, 2025 | 394 | 1.0 | 0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · New financial obligation · Unregistered equity saleDec 1, 2023
- Entered a material agreement · Unregistered equity sale · Director / officer change · Shareholder voteNov 16, 2023
- Director / officer changeAug 8, 2023
- Director / officer change · Shareholder vote · Other material eventJul 28, 2023
- Director / officer changeJul 13, 2023
- Entered a material agreement · Unregistered equity sale · Other material eventJul 6, 2023
- Entered a material agreement · Other material eventJun 16, 2023
- Modified shareholder rights · Amended charter or bylaws · Regulation FD disclosureJun 16, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13D/AFeb 5, 2024
- EFFECTJan 31, 2024
- EFFECTJan 31, 2024
- EFFECTJan 31, 2024
- EFFECTJan 31, 2024
- EFFECTJan 31, 2024
- S-8 POSFORM S-8 POSJan 26, 2024
- S-8 POSFORM S-8 POSJan 26, 2024
- S-8 POSFORM S-8 POSJan 26, 2024
- S-8 POSFORM S-8 POSJan 26, 2024
- POS AMFORM POS AMJan 26, 2024
- S-8 POSFORM S-8 POSJan 26, 2024
- POS AMFORM POS AMJan 26, 2024
- S-8 POSFORM S-8 POSJan 26, 2024
- POS AMFORM POS AMJan 26, 2024
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.